help button home button Am J Pathol ASIP MEMBERSHIP
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hattori, N.
Right arrow Articles by Miyake, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hattori, N.
Right arrow Articles by Miyake, M.
(American Journal of Pathology. 2004;164:1091-1098.)
© 2004 American Society for Investigative Pathology

The Plasminogen Activation System Reduces Fibrosis in the Lung by a Hepatocyte Growth Factor-Dependent Mechanism

Noboru Hattori*, Shinya Mizuno{dagger}, Yuka Yoshida*, Kazuo Chin{ddagger}, Michiaki Mishima§, Thomas H. Sisson, Richard H. Simon, Toshikazu Nakamura{dagger} and Masayuki Miyake*

From the Tazuke Kofukai Medical Research Institute,* Department V of Oncology, Kitano Hospital, Osaka, Japan; Division of Molecular Regenerative Medicine,{dagger} Course of Advanced Medicine, Osaka University Graduate School of Medicine, Suita, Japan; Department of Physical Therapeutics,{ddagger} Kyoto University Hospital of Medicine, Kyoto, Japan; Department of Respiratory Medicine,§ Graduate School of Medicine, Kyoto University, Kyoto, Japan; and the Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan

Mice deficient in the plasminogen activator inhibitor-1 gene (PAI-1-/- mice) are relatively protected from developing pulmonary fibrosis from bleomycin administration. We hypothesized that one of the protective mechanisms may be the ability of the plasminogen system to enhance hepatocyte growth factor (HGF) effects, which have been reported to be anti-fibrotic in the lung. HGF is known to be sequestered in tissues by binding to extracellular matrix components. Following bleomycin administration, we found that HGF protein levels were higher in bronchoalveolar lavage fluid from PAI-1-/- mice compared to wild-type (PAI-1+/+) mice. This increase could be suppressed by administering tranexamic acid, which inhibits plasmin activity. Conversely, intratracheal instillation of urokinase into bleomycin-injured PAI-1+/+ mice to activate plasminogen caused a significant increase in HGF within bronchoalveolar lavage and caused less collagen accumulation in the lungs. Administration of an anti-HGF neutralizing antibody markedly increased collagen accumulation in the lungs of bleomycin-injured PAI-1-/- mice. These results support the hypothesis that increasing the availability of HGF, possibly by enhancing its release from extracellular matrix by a plasmin-dependent mechanism, is an important means by which activation of the plasminogen system can limit pulmonary fibrosis.





This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
I. Yamaguchi, J. M. Lopez-Guisa, X. Cai, S. J. Collins, D. M. Okamura, and A. A. Eddy
Endogenous urokinase lacks antifibrotic activity during progressive renal injury
Am J Physiol Renal Physiol, July 1, 2007; 293(1): F12 - F19.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
H. Matsuoka, T. H. Sisson, T. Nishiuma, and R. H. Simon
Plasminogen-Mediated Activation and Release of Hepatocyte Growth Factor from Extracellular Matrix
Am. J. Respir. Cell Mol. Biol., December 1, 2006; 35(6): 705 - 713.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
A. A. Eddy and A. B. Fogo
Plasminogen Activator Inhibitor-1 in Chronic Kidney Disease: Evidence and Mechanisms of Action
J. Am. Soc. Nephrol., November 1, 2006; 17(11): 2999 - 3012.
[Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
S. Marchand-Adam, A. Fabre, A. A. Mailleux, J. Marchal, C. Quesnel, H. Kataoka, M. Aubier, M. Dehoux, P. Soler, and B. Crestani
Defect of Pro-Hepatocyte Growth Factor Activation by Fibroblasts in Idiopathic Pulmonary Fibrosis
Am. J. Respir. Crit. Care Med., July 1, 2006; 174(1): 58 - 66.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
M. Arras, J. Louahed, V. Simoen, V. Barbarin, P. Misson, S. van den Brule, M. Delos, L. Knoops, J.-C. Renauld, D. Lison, et al.
B Lymphocytes Are Critical for Lung Fibrosis Control and Prostaglandin E2 Regulation in IL-9 Transgenic Mice
Am. J. Respir. Cell Mol. Biol., May 1, 2006; 34(5): 573 - 580.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
H. Fujimoto, E. C. Gabazza, O. Taguchi, Y. Nishii, H. Nakahara, N. E. Bruno, C. N. D'Alessandro-Gabazza, M. Kasper, Y. Yano, M. Nagashima, et al.
Thrombin-Activatable Fibrinolysis Inhibitor Deficiency Attenuates Bleomycin-Induced Lung Fibrosis
Am. J. Pathol., April 1, 2006; 168(4): 1086 - 1096.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
E. Lopez, V. del Pozo, T. Miguel, B. Sastre, C. Seoane, E. Civantos, E. Llanes, M. L. Baeza, P. Palomino, B. Cardaba, et al.
Inhibition of Chronic Airway Inflammation and Remodeling by Galectin-3 Gene Therapy in a Murine Model
J. Immunol., February 1, 2006; 176(3): 1943 - 1950.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
K. Okunishi, M. Dohi, K. Nakagome, R. Tanaka, S. Mizuno, K. Matsumoto, J.-i. Miyazaki, T. Nakamura, and K. Yamamoto
A Novel Role of Hepatocyte Growth Factor as an Immune Regulator through Suppressing Dendritic Cell Function
J. Immunol., October 1, 2005; 175(7): 4745 - 4753.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Society for Investigative Pathology.